Hyderabad, Jan 17: Hyderabad based firm Bharat Biotech has received a government purchase order for supply of 55 lakh doses of Covaxin, a COVID-19 vaccine, said the company will pay compensation to recipients in case of any serious side effects experienced after receiving the antidote.
In the consent form to be signed by the vaccine recipients, Bharat Biotech said, “In case of any adverse events or serious adverse events, you will be provided medically recognised standard of care in the government designated and authorised centres and hospitals.”
“The compensation for serious adverse event will be paid by sponsor (BBIL) in case if the SAE is proven to be causally related to the vaccine,” the consent form said.
Covaxin has demonstrated the ability to produce an antidote against COVID-19 in phase 1 and 2 clinical trials without have major side effects.
However, the clinical efficacy of the vaccine is yet to be established, and it is still being studied in phase 3 clinical trials.
The central licensing authority has granted permission for the sale or distribution of Covaxin for restricted use in emergency situations in public interest as an abundant caution, in clinical trial mode.